Watch out, Pfizer: Affinivax lands $226M in funding to advance Prevnar 13 rival as well as the rest of its pipeline

Nicole DeFeudis

Editor

Affinivax CEO Steven Brugger hit the clinic a couple years ago with an unconventional take on a pneumococcal vaccine designed to dethrone Pfizer’s Prevnar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Watch out, Pfizer: Affinivax lands $226M in funding to advance Prevnar 13 rival as well as the rest of its pipeline

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Watch out, Pfiz­er: Affini­vax lands $226M in fund­ing to ad­vance Pre­vnar 13 ri­val as well as the rest of its pipeline

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Watch out, Pfizer: Affinivax lands $226M in funding to advance Prevnar 13 rival as well as the rest of its pipeline